Clinical trial
Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab…
NCT00479752 · Central European Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00479752 |
|---|---|
| Title | Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer |
| Official title | A Randomized, Open-label Phase II Study Evaluating the Efficacy and Safety of FOLFOX4 + Weekly Cetuximab Versus FOLFOX4+ Biweekly Cetuximab as First-line Therapy in Patients With Metastatic Colorectal Cancer. |
| Acronym | CORE 2 |
| Lead sponsor | Central European Cooperative Oncology Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | FOLFOX4 (Oxaliplatin), Cetuximab |
| Enrollment | 151 |
| Start date | Jan 1, 2008 |
| Primary completion | Jun 1, 2010 |
| Completion | Nov 1, 2015 |
| First posted | May 28, 2007 |
| Last update posted | Feb 18, 2016 |
| Countries | Austria, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Greece, Hungary, Israel, Latvia, Romania, Serbia, Slovakia and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: